Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue, to the Lists of Medications, effective June 2, 2014. The reimbursement of Victoza by the Québec Health Insurance Board will allow people living with type 2 diabetes to have access to a treatment to help better manage diabetes. Québec is the first Canadian province to provide public access to Victoza.

Effective June 2, 2014, Victoza is covered for eligible people in Québec, in association with metformin, for the treatment of type 2 diabetes for those whose glycemic control is inadequate and whose body mass index (BMI) is greater than 30 kg/m(2) when a dipeptidyl peptidase 4 (DPP-4) inhibitor is contraindicated, not tolerated or ineffective. Authorization for an initial request for treatment with Victoza is granted for a maximum of 12 months. When submitting the first request for continuation of treatment, the physician must provide proof of a beneficial effect defined by a reduction in the glycated hemoglobin (HbA1c) of at least 0.5 per cent or by the attainment of a target value of seven per cent or less.

For more details, go to: http://www.fiercepharma.com/press-releases/qu-bec-becomes-first-province-add-victoza-drug-benefit-formulary-treatment-0#ixzz33nHo4Zmx